2-(N-benzyl-N-ethylamino)ethyl chloride hydrochloride | 23510-14-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(N-benzyl-N-ethylamino)ethyl chloride hydrochloride
• 英文别名: N-(2-chloroethyl)-N-ethyl-benzylamine hydrochloride；ethyl-benzyl-(2-chloro-ethyl)-amine; hydrochloride；Aethyl-benzyl-(2-chlor-aethyl)-amin; Hydrochlorid；N-Benzyl-2-chloro-N-ethylethanamine hydrochloride；N-benzyl-2-chloro-N-ethylethanamine;hydrochloride
• CAS: 23510-14-7
• 化学式: C₁₁H₁₆ClN*ClH
• 分子量: 234.169
• InChiKey: AJPDCSIQRYCSPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.17
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  4.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-[1-(4-pentenyl)-4-(3-hydroxyphenyl)-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl]-N'-(2,6-diisopropylphenyl)urea 、 2-(N-benzyl-N-ethylamino)ethyl chloride hydrochloride 生成 N-[1-(4-pentenyl)-4-[3-{2-(N-benzyl-N-ethylamino)ethoxy}phenyl]-1,2-dihydro-2-oxo-1,8-naphthyridin-3-yl]-N'-(2,6-diisopropylphenyl)urea
  参考文献：
  名称：

  Naphthyridine derivatives

  摘要：

  Naphthyridine衍生物的化学式为：##STR1## 其中环A是取代或未取代的吡啶，X为--N(R.sup.2)--CO--(R.sup.2为H、烷基、取代烷基等)，Z为直接键、--NH--、C.sub.1 -C.sub.2烷基或--CH.dbd.CH--，Y为烷基、取代烷基、芳香族基或取代芳香族基等，B为烷基、取代烷基、芳香族基或取代芳香族基，或其酸盐加合物，这些化合物具有酰基辅酶A：胆固醇酰基转移酶抑制活性，并可用作预防或治疗高脂血症、动脉粥样硬化及相关疾病的药物。

  公开号：

  US05843957A1

文献信息

• Naphthyridine derivatives
  申请人：Sumitomo Pharmaceuticals Company, Ltd.

  公开号：US05843957A1

  公开（公告）日：1998-12-01

  Naphthyridine derivative of the formula: ##STR1## wherein Ring A is substituted or unsubstituted pyridine, X is --N(R.sup.2)--CO--(R.sup.2 is H, alkyl, substituted alkyl, etc.), Z is a direct bond, --NH--, C.sub.1 -C.sub.2 alkylene, or --CH.dbd.CH--, Y is alkyl, substituted alkyl, aromatic group or substituted aromatic group, etc., B is alkyl, substituted alkyl, aromatic group or substituted aromatic group, or an acid addition salt thereof, these compounds having acyl-CoA: cholesterol acyl transferase inhibitory activity, and being useful as an agent for prophylaxis or treatment of hyperlipidemia, atherosclerosis, and related diseases thereof.

  Naphthyridine衍生物的化学式为：##STR1## 其中环A是取代或未取代的吡啶，X为--N(R.sup.2)--CO--(R.sup.2为H、烷基、取代烷基等)，Z为直接键、--NH--、C.sub.1 -C.sub.2烷基或--CH.dbd.CH--，Y为烷基、取代烷基、芳香族基或取代芳香族基等，B为烷基、取代烷基、芳香族基或取代芳香族基，或其酸盐加合物，这些化合物具有酰基辅酶A：胆固醇酰基转移酶抑制活性，并可用作预防或治疗高脂血症、动脉粥样硬化及相关疾病的药物。
• NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF
  申请人：SAMJIN PHARMACEUTICAL CO., LTD.

  公开号：US20150141409A1

  公开（公告）日：2015-05-21

  Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis or therapy of gastric ulcer, acute gastritis, chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, or obesity.

  揭示了一种新型的雷巴米特前药，以及其制备方法和用途。此外，提供了一种含有该新型雷巴米特前药作为活性成分的药物组合物。与雷巴米特本身相比，雷巴米特前药的吸收速率增加了25倍，可用于预防或治疗胃溃疡、急性胃炎、慢性胃炎、干眼症、癌症、骨关节炎、类风湿性关节炎或肥胖症。
• Compounds and methods for modulation of estrogen receptors
  申请人：Signal Pharmaceuticals, Inc.

  公开号：US20040082575A1

  公开（公告）日：2004-04-29

  Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-&bgr; over ER-&agr;. Methods are disclosed for modulating ER-&bgr; in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-&bgr;. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

  本发明揭示了调节雌激素受体（ER）的化合物，以及包含这些化合物的药物组合物。在一个具体的实施例中，这些化合物对ER-β比ER-α具有选择性。揭示了在表达具有偏好ER-β的细胞和/或组织中调节ER-β的方法，包括治疗雌激素相关疾病的方法，例如乳腺癌、睾丸癌、骨质疏松症、子宫内膜异位症、心血管疾病、高胆固醇血症、前列腺增生、前列腺癌、肥胖、潮热、皮肤影响、情绪波动、记忆力下降、尿失禁、脱发、白内障、自然激素失衡以及与环境化学物质暴露相关的不良生殖影响。
• 1,5-Benzothiazephine derivatives, processes for preparing the same and pharmaceutical compositions
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：EP0158339A2

  公开（公告）日：1985-10-16

  Novel 1,5-benzothiazepine derivatives of the formula: wherein R1 is hydrogen or lower alkyl, R2 is hydrogen, lower alkanoyl or benzyl, R3 is hydrogen or lower alkyl and either one of R4 and R5 is hydrogen and the other is chlorine, or a pharmaceutically acceptable acid addition salt thereof are disclosed. In form of pharmaceutical compositions the said derivative (I) and its salt have a potent platelet aggregation-inhibiting activity.

  式中的新型 1，5-苯并硫氮杂卓衍生物： 其中 R1 是氢或低级烷基，R2 是氢、低级烷酰基或苄基，R3 是氢或低级烷基，R4 和 R5 中的一个是氢，另一个是氯，或其药学上可接受的酸加成盐。在药物组合物中，上述衍生物 (I) 及其盐具有强效的血小板聚集抑制活性。
• NOVEL NAPHTHYRIDINE DERIVATIVES
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0947515A1

  公开（公告）日：1999-10-06

  Naphthyridine derivative of the formula: wherein Ring A is substituted or unsubstituted pyridine ring, X is ―N(R2)―CO― (R2 is H, alkyl, substituted alkyl, etc.), Z is a direct bond, ―NH―, C1-2 alkylene, or ―CH=CH―, Y is aromatic group or substituted aromatic group, L is alkyl, substituted alkyl, aromatic group or substituted aromatic group, or an acid addition salt thereof, these compounds exhibiting acyl-CoA: cholesterol acyl transferase inhibitory activity, and being useful as an agent for prophylaxis or treatment of hyperlipidemia, atherosclerosis, and related diseases thereof.

  式中的萘啶衍生物： 其中环 A 是取代或未取代的吡啶环，X 是-N(R2)-CO-（R2 是 H、烷基、取代烷基等），Z 是直接键、-NH-、C1-2 亚烷基或-CH=CH-，Y 是芳香基团或取代芳香基团，L 是烷基、C1-2 亚烷基或-CH=CH-。Z为直接键、-NH-、C1-2亚烷基或-CH=CH-，Y为芳香基团或取代的芳香基团，L为烷基、取代的烷基、芳香基团或取代的芳香基团，或其酸加成盐，这些化合物具有酰基-CoA：胆固醇酰基转移酶抑制活性，可作为预防或治疗高脂血症、动脉粥样硬化及其相关疾病的药物。